Tesla
TSLA
MicroStrategy
MSTR
MARA Holdings
MARA
Apple
AAPL
Microsoft
MSFT
US Stock MarketDetailed Quotes
YMAB Y-mAbs Therapeutics
- 9.430
- -0.340-3.48%
Close Dec 13 16:00 ET
- 9.430
- 0.0000.00%
Post 16:20 ET
422.36MMarket Cap-17.46P/E (TTM)
9.830High9.310Low228.40KVolume9.800Open9.770Pre Close2.16MTurnover0.84%Turnover RatioLossP/E (Static)44.79MShares20.90052wk High4.57P/B255.31MFloat Cap6.09052wk Low--Dividend TTM27.07MShs Float55.215Historical High--Div YieldTTM5.32%Amplitude2.700Historical Low9.449Avg Price1Lot Size
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Y-mAbs Therapeutics Stock Forum
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
Y-mAbs Therapeutics (NASDAQ: YMAB)presented preclinical data and trial progress for its CD38-SADA platform at the 2024 ASH Annual Meeting. The preclinical data demonstrated selective binding and anti-tumor efficacy of CD38-SADA when used with Lutetium 177-DOTA in treating Non-Hodgkin Lymphoma (NHL).
The company also...
No comment yet